PlainPharmaWatch

CMS Open Payments · Tool

GC America Inc. vs Astellas Pharma Europe Ltd

Side-by-side comparison of CMS Open Payments data for Program Year 2024. Select different companies below to start a new comparison.

A larger reported total is not "better" or "worse", it is a neutral fact about disclosure volume; a reported payment documents a financial relationship, not evidence of wrongdoing.

Compare Different Companies

vs

Relationship comparison

Which recorded payment profile is more concentrated?

Astellas Pharma Europe Ltd has the more concentrated recorded General Payments recipient profile in Program Year 2024: its recipient-distribution HHI is 1,263, versus 479 for the other company. Its single largest recorded recipient represents 0.3% of that company's General Payments recipient total.

HHI summarizes how payments are distributed across recorded recipients: higher means a less evenly distributed recipient pattern. This is a description of CMS-reported General Payments only, not a finding about conduct, prescribing, quality, or wrongdoing. Read it with the recipient count and underlying records below.

GC America Inc.
HHI 479 · top recipient 0.2%
Ranked #1,305 of 1,838 companies by HHI
Astellas Pharma Europe Ltd
HHI 1,263 · top recipient 0.3%
Ranked #928 of 1,838 companies by HHI

Payment Overview

Company A

GC America Inc.

Total Payments
$524.2K
% of Industry
0.0%
Transactions
2,479
Avg per Transaction
$211.46
Recipients
2,479
Avg per Recipient
$211.46
Payment Types
6
Top Payment Type
Honoraria
Total Payments
$523.2K
% of Industry
0.0%
Transactions
167
Avg per Transaction
$3.1K
Recipients
167
Avg per Recipient
$3.1K
Payment Types
4
Top Payment Type
Consulting Fee

Highlighted values indicate the higher figure for each metric.

Total payments compared

GC America Inc. vs Astellas Pharma Europe Ltd - total reported payments in CMS Open Payments PY2024

GC America Inc.$524.2KAstellas Pharma Europe Ltd$523.2K

Payment Types Breakdown

GC America Inc.

Honoraria $354.5K

67.6%

Food and Beverage $69.0K

13.2%

Compensation for Faculty or Speaker (Medical Education) $38.0K

7.2%

Royalty or License $36.9K

7.0%

Travel and Lodging $25.6K

4.9%

Gift $240.28

0.0%

Astellas Pharma Europe Ltd

Consulting Fee $287.7K

55.0%

Travel and Lodging $222.5K

42.5%

Compensation for Services Other Than Consulting $11.4K

2.2%

Food and Beverage $1.6K

0.3%

Top 5 General-Payment Recipients

This list uses CMS detailed General Payments records only; it excludes research and ownership/investment records, so it does not equal the all-category totals above. A reported payment documents a financial relationship, not evidence of wrongdoing; a higher total reflects reporting volume, not conduct. Verify directly at openpaymentsdata.cms.gov.

GC America Inc.

  1. 1

    ANTONINO GESUINO SECCHI

    $78,924.89 · 12 txns

  2. 2

    BRIAN B. NOVY

    $62,688.13 · 18 txns

  3. 3

    ROBERT D MARUS

    $21,353.53 · 11 txns

  4. 4

    MATTHEW ARASH NEJAD

    $18,481.47 · 14 txns

  5. 5

    MARC JOSEPH GEISSBERGER

    $16,036.85 · 7 txns

Astellas Pharma Europe Ltd

  1. 1

    STEPHEN FREEDLAND

    $151,538.63 · 27 txns

  2. 2

    TERENCE FRIEDLANDER

    $45,633.38 · 10 txns

  3. 3

    PETER O DONNELL

    $41,977.00 · 5 txns

  4. 4

    STEVEN GOLDSTEIN

    $38,338.79 · 22 txns

  5. 5

    VADIM S KOSHKIN

    $33,606.52 · 17 txns

Summary Comparison

Metric GC America Inc. Astellas Pharma Europe Ltd
Total Payments $524.2K $523.2K
% of Industry Total 0.0% 0.0%
Transaction Count 2,479 167
Avg per Transaction $211.46 $3.1K
Recipient Count 2,479 167
Avg per Recipient $211.46 $3.1K
Payment Type Count 6 4
Top Payment Type Honoraria Consulting Fee

Data Source: Centers for Medicare & Medicaid Services (CMS) Open Payments, Program Year 2024. Data includes general payments, research payments, and physician ownership/investment interests as required by the Physician Payments Sunshine Act. All companies in the CMS Open Payments company corpus are available in the selector. Browse all companies →

Every figure on PlainPharmaWatch is rendered directly from federal source data, no number is typed in by an editor. This page draws directly on federal source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.